Arcus biosciences stock.

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced it will report financial results and key pipeline updates for the first quarter ended March 31, 2022 after the U.S. …Track Arcus Biosciences Inc (RCUS) Stock Price, Quote, latest community messages, chart, news and other stock related information.Find out the latest news, events, and updates on Arcus Biosciences, a biotechnology company that develops cancer immunotherapies. See the stock …At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you …

Zimberelimab was in-licensed by Arcus to enable the development of precision combination regimens with full line-of-sight to the commercialization of innovative therapies for all patients who may benefit. Arcus is evaluating zimberelimab in combination with multiple molecules within the Arcus portfolio, including several registrational Phase 3 ...Arcus Biosciences Inc (RCUS) Stock Price & News - Google Finance Home RCUS • NYSE Arcus Biosciences Inc Follow Share $14.06 Nov 27, 3:45:00 AM GMT-5 · USD · NYSE · Disclaimer search...

Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is …

Arcus Biosciences Inc (RCUS) registered a 6.71% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 6.71% in intraday trading to $16.07 this Friday, 12/01/23, hitting a weekly high. The stock’s 5-day price performance is 14.30%, and it has moved by 1.58% in 30 days.Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, ... 2023, and restricted stock units to acquire a total of 17,700 shares of the Company’s common stock.FOSTER CITY, Calif., & HAYWARD, Calif., May 15, 2023--Gilead Sciences, Inc. (Nasdaq:GILD) and Arcus Biosciences, Inc. (NYSE:RCUS) today announced that the companies have expanded the previously ...Shares of the cancer specialist Arcus Biosciences ( RCUS -1.07%) jumped by approximately 31% during the month of November, according to data from S&P Global Market Intelligence. The biotech's ...

Arcus Biosciences, Inc. (NYSE:RCUS) Q3 2023 Earnings Call Transcript. Arcus Biosciences, Inc. (NYSE:RCUS) Q3 2023 Earnings Call Transcript November 8, 2023 Operator: Thank you and welcome to the call.

While ratings are subjective and will change, the latest Arcus Biosciences ( RCUS) rating was a maintained with a price target of $46.00 to $36.00. The current price Arcus Biosciences ( RCUS) is ...

Overview Stock Screener Earnings Calendar Sectors NYSE | RCUS U.S.: NYSE Arcus Biosciences Inc. Watch list NEW Set a price target alert After Hours Last Updated: Nov 14, 2023 4:08 p.m. EST... Calendar Arcus Biosciences, Inc. Equities. RCUS. US03969F1093. Market Closed - Nyse. Other stock markets.In a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on Arcus Biosciences (RCUS - Research Report), with a pr...A high-level overview of Arcus Biosciences, Inc. (RCUS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Arcus Biosciences Inc Stock Price: Bottom Line. As of March 24, 2023, Arcus Biosciences Inc’s stock price is $17.62, which is up 7.7% from its previous closing price. At AAII, we stress that investors should never buy or sell a stock solely based on its stock price. Past returns do not guarantee future performance.

According to the issued ratings of 8 analysts in the last year, the consensus rating for Arcus Biosciences stock is Moderate Buy based on the current 1 hold rating and 7 buy ratings for RCUS. The average twelve-month price prediction for Arcus Biosciences is $43.13 with a high price target of $70.00 and a low price target of $23.00.Arcus Biosciences, Inc. (NYSE:RCUS) Q3 2023 Earnings Call Transcript. Arcus Biosciences, Inc. (NYSE:RCUS) Q3 2023 Earnings Call Transcript November 8, 2023 Operator: Thank you and welcome to the call.Nov 29, 2023 · Powered By Q4 Inc. 5.111.2.6. See updates on stock information on the Arcus Biosciences site and contact Investor Relations here. Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted 12 new employees options to purchase a total of 31,200 shares of the Company’s common stock at an exercise price ...Arcus Biosciences stock has received a consensus rating of buy. The average rating score is and is based on 19 buy ratings, 3 hold ratings, and 0 sell ratings. What was the 52-week low for Arcus ...Track Arcus Biosciences Inc (RCUS) Stock Price, Quote, latest community messages, chart, news and other stock related information.Nov 27, 2023 · Arcus Biosciences, Gilead shares are down after sharing data about new lung cancer drug. Shares of Arcus Biosciences Inc. RCUS, -1.23% were down 17.2% in premarket trading on Tuesday, the day after the company said the experimental treatment for metastatic non-small cell lung cancer that ...

Check if RCUS Stock has a Buy or Sell Evaluation. RCUS Stock Price (NYSE), Forecast, Predictions, Stock Analysis and Arcus Biosciences Inc. News.

Bank of America Securities analyst Jason Zemansky maintained a Hold rating on Arcus Biosciences ( RCUS – Research Report) today and set a price target of $21.00. The company’s shares closed ...A high-level overview of Arcus Biosciences, Inc. (RCUS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Find the latest Arcus Biosciences, Inc. (RCUS) stock quote, history, news and other vital information to help you with your stock trading and investing.Nov 29, 2023 · Powered By Q4 Inc. 5.111.2.6. See updates on stock information on the Arcus Biosciences site and contact Investor Relations here. Arcus Biosciences, Inc. (RCUS) NYSE - NYSE Delayed Price. Currency in USD Follow 2W 10W 9M 16.41 -0.30 (-1.80%) At close: 04:00PM EDT 16.14 -0.27 (-1.65%) After …Arcus Biosciences, Inc. (RCUS) NYSE - NYSE Delayed Price. Currency in USD Follow 2W 10W 9M 16.41 -0.30 (-1.80%) At close: 04:00PM EDT 16.14 -0.27 (-1.65%) After …An in-depth examination of risks revealed 2 warning signs for Arcus Biosciences that readers should think about before committing capital to this stock. Of course, you might find a fantastic ...Oct 31, 2023 · Arcus Biosciences, Inc. Appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its ...

AB308 is a second investigational anti-TIGIT monoclonal antibody that is Fc-enabled. AB308 in combination with zimberelimab is currently being investigated in a Phase 1b study of people with advanced solid and hematologic malignancies. 00:00. 02:45.

View the latest Arcus Biosciences Inc. (RCUS) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.99. This compares to earnings of $3.71 per share a year ago.Arcus Biosciences, Inc. Common Stock (RCUS) Stock Price, Quote, News & History | Nasdaq Created with Sketch. Market Activity Funds + ETFs News + Insights P/E & PEG Ratios when trading,...Dec 1, 2023 · See the latest Arcus Biosciences Inc stock price (RCUS:XNYS), related news, valuation, dividends and more to help you make your investing decisions. US03969F1093. Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and …An in-depth examination of risks revealed 2 warning signs for Arcus Biosciences that readers should think about before committing capital to this stock. Of course, you might find a fantastic ...Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting ...15 мая 2023 г. ... Gilead is paying $35 million cash to expand an existing oncology partnership with Arcus Biosciences into inflammatory diseases.Nov 27, 2023 · Arcus Biosciences, Gilead shares are down after sharing data about new lung cancer drug. Shares of Arcus Biosciences Inc. RCUS, -1.23% were down 17.2% in premarket trading on Tuesday, the day after the company said the experimental treatment for metastatic non-small cell lung cancer that ... Arcus Biosciences-stock Arcus Biosciences Inc Registered Shs Stock , RCUS 14.34 +0.46 +3.35% 01:55:56 PM EDT 11/24/2023 NYSE Add to watchlist 13.88 …During the last session, Arcus Biosciences Inc (NYSE:RCUS)’s traded shares were 0.88 million, with the beta value of the company hitting 0.75. At the end of the trading day, the stock’s price was $16.01, reflecting an intraday loss of -2.67% or -$0.44. The 52-week high for the RCUS share is $36.

FOSTER CITY, Calif., & HAYWARD, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced updated results from an interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score …High levels of adenosine present in the tumor microenvironment have direct immunosuppressive impact on T-cell function and activation. AB928, a selective, small-molecule dual A2aR/A2bR antagonist, potently blocks the effects of adenosine and, in combination with chemotherapy or anti-PD-1, may have a more profound effect on …Arcus Biosciences, Inc. (NYSE:RCUS) Q3 2023 Earnings Call Transcript. Arcus Biosciences, Inc. (NYSE:RCUS) Q3 2023 Earnings Call Transcript November 8, 2023 Operator: Thank you and welcome to the call.Arcus Biosciences Inc Stock Price History. Arcus Biosciences Inc’s price is currently up 3.95% so far this month. During the month of April, Arcus Biosciences Inc’s stock price has reached a high of $19.03 and a low of $16.94. Over the last year, Arcus Biosciences Inc has hit prices as high as $36.13 and as low as $15.70. Year to date ...Instagram:https://instagram. top hft companiesbest penny stocks to invest in todaybest software to analyze stockslargest forex brokers in the world Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders.Arcus Biosciences saw a increase in short interest in the month of September. As of September 30th, there was short interest totaling 6,620,000 shares, an increase of 1.4% from the previous total of 6,530,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a … best dental insurance for crownsdollar general share price Arcus Biosciences (RCUS) stock price prediction is 40.382134862897 USD. The Arcus Biosciences stock forecast is 40.382134862897 USD for 2024 November 27, ...Arcus Biosciences Stock Forecast. All Analysts Top Analysts Stock Price Forecast. According to 10 stock analysts, the average 12-month stock price forecast for RCUS stock stock is $42.6, which predicts an increase of 165.09%. The lowest target is $23 and the highest is $70. On average, analysts rate RCUS stock stock as a strong buy. spg. Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -2.83% and 4.29%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?In a report released on March 1, Daina Graybosch from SVB Securities maintained a Buy rating on Arcus Biosciences ( RCUS – Research Report ). The company’s shares closed yesterday at $17.57 ...